5-((4-(tert-Butoxycarbonyl)piperazin-1-yl)methyl)-1-methyl-1H-pyrazole-4-carboxylic acid

Catalog No. :
ACNDMB279
CAS No. :
1698549-81-3
Molecular Formula :
C15H24N4O4
Molecular Weight :
324.38

IUPAC Name:5-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-1-methyl-1H-pyrazole-4-carboxylic acid

5-((4-(tert-Butoxycarbonyl)piperazin-1-yl)methyl)-1-methyl-1H-pyrazole-4-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$282.00Login to see priceInquiryInquiry
100mg98%$414.00Login to see priceInquiryInquiry
250mg98%$582.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-((4-(tert-Butoxycarbonyl)piperazin-1-yl)methyl)-1-methyl-1H-pyrazole-4-carboxylic acid
IUPAC Name5-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-1-methyl-1H-pyrazole-4-carboxylic acid
MDL No.MFCD31629371
Molecular FormulaC15H24N4O4
Molecular Weight324.38
SMILESO=C(C1=C(CN2CCN(C(OC(C)(C)C)=O)CC2)N(C)N=C1)O
InChI KeyMBEAJWHCJZLBBM-UHFFFAOYSA-N
Synonym5-({4-[(tert-butoxy)carbonyl]piperazin-1-yl}methyl)-1-methyl-1h-pyrazole-4-carboxylic acid;1-Piperazinecarboxylic acid, 4-[(4-carboxy-1-methyl-1H-pyrazol-5-yl)methyl]-, 1-(1,1-dimethylethyl) ester
CAS No.1698549-81-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACNDMB279 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACNDMB279 route product structure diagram
    ACNDMB2791698549-81-3
Inquiry

2. ACNDMB279 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACNDMB279 route product structure diagram
    ACNDMB2791698549-81-3
Inquiry

Comments (0)